Document is current

Article History

Accepted: 14 January 2024

First Online: 1 February 2024

Declarations

:

: The design, study conduct, and financial support for the study were provided by F. Hoffmann-La Roche Ltd. and Genentech, Inc.

: Shih-Wen Lin, Sheila Shapouri, Mei Wu, and Eunice Kim are employees of Genentech, Inc. and may own stocks/and or options from F. Hoffmann-La Roche Ltd. Hélène Parisé and Eric Bercaw are employees of Medicus Economics, LLC and received consulting fees for research from Genentech, Inc. Matthew Matasar is an employee of the Rutgers Cancer Institute of New Jersey. He has appointments for consultancy or is an advisory board member to Genentech, Inc., F. Hoffmann-La Roche Ltd, Bayer, Juno, Seattle Genetics, Takeda, Teva, and Merck; has institutional research funding from Genentech, Inc., F. Hoffmann-La Roche Ltd, Bayer, GM Biosciences, Immunovaccine Technologies, Janssen, Pharmacyclics, and Seattle Genetics; has received honoraria or stipends from Genentech, Inc., F. Hoffmann-La Roche Ltd, ADC Therapeutics, AstraZeneca, Bayer, BMS, Celgene, Epizyme, Immunovaccine Technologies, IMV Therapeutics, Janssen, Kite, Pharmacyclics, Regeneron, Seagen, Seattle Genetics, Takeda, and Teva; and he owns stocks/and or options from Merck.

: Not applicable.

: Not applicable.

: Not applicable.

: The data that support the findings of this study are available in this article. The model is not publicly available because of its intrinsic commercial value and cannot be shared for legal reasons.

: Not applicable.

: Genentech, Inc. and Medicus Economics, LLC participated in the design of the research, the analysis and interpretation of finding, and in the manuscript writing, review, and approval. All authors contributed to the development of the manuscript and maintained control over the final content.